Alexander Miethke is a Gastroenterology physician affiliated with Cincinnati Children's Hospital Medical Center. OpenAlex indexes 134 publications with 3,185 citations (h-index 30); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
- MRI Biomarkers in as Predictor of Clinical Endpoints in Pediatric Autoimmune Liver Disease
Sponsor: Children's Hospital Medical Center, Cincinnati
- MRI Based Biomarkers in Pediatric Autoimmune Liver Disease
Sponsor: Children's Hospital Medical Center, Cincinnati
- Biliary Atresia Study in Infants and Children
Sponsor: Arbor Research Collaborative for Health
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Takeda Pharmaceuticals U.S.A., Inc.Program year202510 payments$14,986openpaymentsdata.cms.gov ↗
- Perspectum Diagnostics LtdProgram year20251 payment
- Mirum Pharmaceuticals, Inc.Program year20242 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
45.8%Calcineurin inhibitor45.8%Tacrolimus100%Part D<11 patientsAnti-infectives
31.2%Penicillin-class Antibacterial31.2%Penicillin V Potassium100%Part D<11 patientsCardiovascular
22.9%ACE inhibitor22.9%Lisinopril100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
4 NIH research awards on record, funded 2012–2026 per NIH RePORTER. The latest:
- The Roles of MRP9 in cholangiocyte metabolism
Cincinnati Childrens Hosp Med Ctr
FY2026$763,829R01DK140321 - Clinical Center for Cholestatic Liver Disease in Children
Cincinnati Childrens Hosp Med Ctr
FY2026$599,685U01DK062497 - Genetic and microenvironmental regulation of macrophage functions driving biliary fibrosis in pediatric PSC
Cincinnati Childrens Hosp Med Ctr
FY2026$533,386R01DK095001
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Maralixibat in progressive familial intrahepatic cholestasis (MARCH-PFIC): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
The Lancet. Gastroenterology & hepatology
2024 - Maralixibat for the treatment of PFIC: Long‐term, IBAT inhibition in an open‐label, Phase 2 study
Hepatology Communications
2022 - Farnesoid X receptor antagonizes macrophage-dependent licensing of effector T lymphocytes and progression of sclerosing cholangitis
Science Translational Medicine
2022 - Impact of long‐term administration of maralixibat on children with cholestasis secondary to Alagille syndrome
Hepatology Communications
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Andrea Beaton, MD
Cincinnati Children's Hospital Medical Center
Prasad Devarajan, MD
Cincinnati Children's Hospital Medical Center
Stuart Goldstein, MD
Cincinnati Children's Hospital Medical Center
Andrew Redington, MD
Cincinnati Children's Hospital Medical Center
Charles Rice, MD
The Rockefeller University
Edward Loftus, MD
Mayo Clinic Rochester
Naga Chalasani, MD
Indiana University School of Medicine
Bruce Sands, MD
Icahn School of Medicine at Mount Sinai
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”